An analytical comparability study is required following any significant change in the manufacturing process of an Advanced Therapy Medicinal Product (ATMP). Common triggers include scaling up production (e.g., moving from adherent to AAV scalable suspension systems), changing manufacturing sites, altering a key raw material, or modifying a purification step. For an Investigational Medicinal Product Dossier (IMPD) submission to the MHRA, this data is fundamental to ensuring patient safety and product consistency.

A well-designed protocol de-risks the program by prospectively defining the analytical strategy, acceptance criteria, and statistical approach before the post-change material is even manufactured. This prevents post-hoc data justification and aligns the development team and regulatory body on the definition of comparability, minimizing clinical risk and potential delays in the 18-24 month IND timeline.

Comparability for AAV vectors is assessed across multiple domains. Key areas include physicochemical properties (particle size, aggregation), quantity and purity (full/empty capsid ratio, residual DNA/protein), identity (capsid and genome confirmation), and biological activity (in vitro potency assays, infectivity). A comprehensive data package covering these attributes is required.

Manufacturing process evolution is a given for any successful AAV therapeutic program. As production scales and processes are refined for efficiency, sponsors must provide definitive analytical evidence to regulators that the product remains comparable to the material used in foundational IND-enabling toxicology studies.

A prospective, scientifically-grounded comparability protocol is the primary tool for managing this process. It establishes the framework for evaluating the impact of manufacturing changes on the key quality attributes (CQAs) of the AAV vector. This framework is a regulatory necessity for submissions to agencies like the MHRA and FDA.